Regarding the mechanisms of Extended-Spectrum Beta-Lactamase (ESBL) production in Gram-negative bacteria, all of the following statements are TRUE EXCEPT:

Explanation

## Mechanism of ESBL Resistance — All EXCEPT **Key Point:** The FALSE statement is Option D. While ESBL genes are *derived* from TEM and SHV parent enzymes via point mutations, these genes are **plasmid-encoded**, not chromosomal. The stem of Option D incorrectly states they arise from "point mutations in **chromosomal** TEM and SHV beta-lactamases," conflating the evolutionary origin with the current genomic location. ### Why Option D is FALSE (the EXCEPT answer) Classic ESBLs (TEM-2, TEM-3, SHV-2, etc.) did indeed arise from point mutations in TEM-1 and SHV-1 parent enzymes that expanded substrate specificity to third-generation cephalosporins. However, in clinical ESBL-producing isolates, these genes are **plasmid-borne**, not chromosomal. The plasmid location is precisely what enables rapid horizontal gene transfer (conjugation) between Enterobacteriaceae species. Describing them as "chromosomal" is factually incorrect for the vast majority of clinically relevant ESBLs [Mandell, Douglas & Bennett's Principles and Practice of Infectious Diseases, 9th ed., Ch. 17; Murray's Medical Microbiology, 9th ed.]. ### Why the Other Options Are TRUE | Option | Statement | Verdict | |--------|-----------|---------| | **A** | ESBL enzymes are inhibited by clavulanic acid / tazobactam | **TRUE** — ESBLs are characteristically inhibited by beta-lactamase inhibitors *in vitro*; this is the basis of the phenotypic ESBL confirmatory test (ceftazidime ± clavulanate disk synergy test). | | **B** | ESBL-producing organisms remain susceptible to carbapenems | **TRUE** — ESBL enzymes cannot hydrolyze the carbapenem ring; carbapenems are first-line for serious ESBL infections. | | **C** | ESBL genes are plasmid-located and horizontally transferable | **TRUE** — Plasmid-mediated transfer is the primary driver of ESBL dissemination in healthcare and community settings. | **High-Yield:** The ESBL phenotypic confirmatory test exploits the inhibitor susceptibility of ESBLs: a ≥5 mm increase in zone diameter with ceftazidime + clavulanate vs. ceftazidime alone confirms ESBL production (CLSI criteria). This directly confirms Option A is TRUE. **Clinical Pearl:** CTX-M-type ESBLs (especially CTX-M-15), which are NOT derived from TEM/SHV mutations but from *Kluyvera* chromosomal AmpC genes, are now the most prevalent ESBLs globally — further highlighting that the "chromosomal" descriptor in Option D is misleading and incorrect for the plasmid-borne TEM/SHV-derived ESBLs described.